{"paper_id":"0b2b6784-3b9d-428a-a146-3fa5eb30cb24","body_text":"The role of the junctional zone in the diagnosis and treatment of adenomyosis\n- Authors: Nagorneva S.V.1, Shalina M.A.1, Yarmolinskaya M.I.1\n-\nAffiliations:\n- The Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott\n- Issue: Vol 75, No 2 (2026)\n- Pages: 54-63\n- Section: Original study articles\n- Submitted: 09.10.2025\n- Accepted: 08.04.2026\n- Published: 29.04.2026\n- URL: https://journals.eco-vector.com/jowd/article/view/692632\n- DOI: https://doi.org/10.17816/JOWD692632\n- EDN: https://elibrary.ru/TONJJH\n- ID: 692632\nCite item\nAbstract\nBackground: Timely diagnosis of adenomyosis remains important due to the high incidence of the disease among women of reproductive age. Interest in using myometrial transition zone parameters in diagnostic algorithms has persisted since the first data on it as a marker for adenomyosis emerged. However, the role and clinical significance of the junctional zone in patients with adenomyosis currently remain a subject of scientific debate due to the inconsistency of the available data. Furthermore, the literature lacks information on its dynamics and changes under the influence of various therapies.\nAim: The aim of this study was to evaluate the diagnostic significance of the junctional zone parameters in adenomyosis and their changes during the treatment of the disease.\nMethods: A prospective cross-sectional, single-center study was conducted. All patients underwent ultrasound examination using an expert-class GE Voluson E10 (GE Healthcare, USA) with IC5-9-D and RIC6-12-D probes, color Doppler mapping, elastography, and volume reconstruction. To diagnose adenomyosis, we used the results of a comprehensive ultrasound examination using a patented proprietary scoring method. All patients underwent a junctional zone assessment.\nResults: 344 women were examined: 287 with a diagnosis of adenomyosis, of whom 273 had complaints and 14 were without complaints, and 57 patients in the control group. Significant differences were found in the assessment of the junctional zone in the main groups and the control group (p = 0.37). In 156 patients, the junctional zone was assessed before and 6 months after treatment of adenomyosis using several regimens: resveratrol 100 mg daily, dienogest 2 mg daily, and resveratrol 100 mg + dienogest 2 mg daily. During treatment, the average size of the junctional zone decreased, especially after combined treatment (p = 0.03).\nConclusion: The significance of the assessment of the junctional zone in the diagnosis of adenomyosis is currently small, due to the peculiarities of its visualization in some patients, however, the assessment of the thickness and uniformity of the junctional zone can be successfully used in the complex diagnosis of the disease. Furthermore, dynamic assessment of these parameters is a useful tool for monitoring treatment effectiveness, particularly during maintenance therapy.\nFull Text\nAbout the authors\nStanislava V. Nagorneva\nThe Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott\nAuthor for correspondence.\nEmail: stanislava_n@bk.ru\nORCID iD: 0000-0003-0402-5304\nSPIN-code: 5109-7613\nMD, Cand. Sci. (Medicine)\nRussian Federation, 3 Mendeleevskaya Line, Saint Petersburg, 199034Maria A. Shalina\nThe Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott\nEmail: amarus@inbox.ru\nORCID iD: 0000-0002-5921-3217\nSPIN-code: 6673-2660\nMD, Cand. Sci. (Medicine)\nRussian Federation, 3 Mendeleevskaya Line, Saint Petersburg, 199034Maria I. Yarmolinskaya\nThe Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott\nEmail: m.yarmolinskaya@gmail.com\nORCID iD: 0000-0002-6551-4147\nSPIN-code: 3686-3605\nMD, Dr. Sci. (Medicine), Professor, Professor of the Russian Academy of Sciences, Honored Scientist of the Russian Federation\nRussian Federation, 3 Mendeleevskaya Line, Saint Petersburg, 199034References\n- Demidov VN. Extragenital endometriosis ultrasound diagnostics. Ultrasound and Functional Diagnostics. 2010;(3):102–111. EDN: NCZEVT\n- Yarmolinskaya MI, Ailamazyan EK. Genital endometriosis. Various aspects of the problem. St. Petersburg: Eco-Vector; 2017: 615. (In Russ.) EDN: XYSZVJ\n- Van den Bosch T, Dueholm M, Leone FP, et al. Terms, definitions and measurements to describe sonographic features of myometrium and uterine masses: a consensus opinion from the Morphological Uterus Sonographic Assessment (MUSA) group. Ultrasound Obstet Gynecol. 2015;46(3):284–98. doi: 10.1002/uog.14806\n- Harmsen MJ, Van den Bosch T, de Leeuw RA, et al. Consensus on revised definitions of Morphological Uterus Sonographic Assessment (MUSA) features of adenomyosis: results of modified Delphi procedure. Ultrasound Obstet Gynecol. 2022;60(1):118–131. doi: 10.1002/uog.24786 EDN: OGHKJK\n- Kepkep K, Tuncay YA, Göynümer G, Tutal E. Transvaginal sonography in the diagnosis of adenomyosis: which findings are most accurate. Ultrasound Obstet Gynecol. 2007;30:341–345. doi: 10.1002/uog.3985\n- Benagiano G, Brosens I. Adenomyosis and endometriosis have a common origin. The Journal of Obstetrics and Gynecology of India. 2011;61(2):146–152. doi: 10.1007/s13224-011-0030-y EDN: BOOYKY\n- Hricak H, Alpers C, Crooks LE, Sheldon PE. Magnetic resonance imaging of the female pelvis: initial experience. AJR Am J Roentgenol. 1983;141(6):1119–28. doi: 10.2214/ajr.141.6.1119\n- Exacoustos C, Brienza L, Di Giovanni A, et al. Adenomyosis: three-dimensional sonographic findings of the junctional zone and correlation with histology. Ultrasound Obstet Gynecol. 2017;37(4):471–479. doi: 10.1002/uog.8900\n- Exacoustos C, Luciano D, Corbett B, et al The uterine junctional zone: a 3-dimensional ultrasound study of patients with endometriosis. Am J Obstet Gynecol. 2013;209(3):248.e1–7. doi: 10.1016/j.ajog.2013.06.006\n- Rasmussen CK, Hansen ES, Ernst E, Dueholm M. Two- and three-dimensional transvaginal ultrasonography for diagnosis of adenomyosis of the inner myometrium. Reprod Biomed Online. 2019;38(5):750–760. doi: 10.1016/j.rbmo.2018.12.033\n- Yarmolinskaya MI, Shalina MA, Nagorneva SV. New possibilities of ultrasound diagnostics and modern strategy of drug therapy for adenomyosis. Farmateka. 2022;29(6):101–108. doi: 10.18565/pharmateca.2022.6.101-107 EDN: CVBLKM\n- Tomassetti C, Johnson NP, Petrozza J, et al. International working group of AAGL, ESGE, ESHRE and WES. An international terminology for endometriosis, 2021. J Minim Invasive Gynecol. 2021;28(11):1849–1859. doi: 10.1016/j.jmig.2021.08.032 EDN: SNDUQU\n- Yarmolinskaya MI, Shalina MA, Nagorneva SV. Modern approaches to classification of adenomyosis. Journal of Obstetrics and Women’s Diseases. 2023;72(1):97–108. doi: 10.17816/JOWD121307. EDN: NZZPMZ\n- Patent RUS № RU2764106/ 13.01.2022. Nagorneva SV, Shalina MA, Yarmolinskaya MI, et al. Method of diagnosis of adenomyosis. Available from: https://patenton.ru/patent/RU2764106C1?ysclid=moctdb49zd267073198 (In Russ.) EDN: BCYRSL\n- Fusi L, Cloke B, Brosens JJ. The uterine junctional zone. Best Pract Res Clin Obstet Gynaecol. 2006;20(4):479–91. doi: 10.1016/j.bpobgyn.2006.02.001\n- Chan RW, Schwab KE, Gargett CE. Clonogenicity of human endometrial epithelial and stromal cells. BiolReprod. 2004;70(6):1738–1750. doi: 10.1095/biolreprod.103.024109\n- Maheshwari A, Gurunath S, Fatima F, Bhattacharya S. Adenomyosis and subfertility: a systematic review of prevalence, diagnosis, treatment and fertility outcomes. Hum Reprod Update. 2012;18(4):374–92. doi: 10.1093/humupd/dms006\n- Mogilnaja GM, Simovonik AN. The junctional zone of the uterus and its predictors in the diagnosis of adenomyosis. Crimean Journal of Experimental and Clinical Medicine. 2018;(1):55–66. EDN: UUXGVK\n- Meylaerts LJ, Wijnen L, Grieten M, et al. Junctional zone thickness in young nulliparous women according to menstrual cycle and hormonal contraception use. Reprod Biomed Online. 2017;34(2):212–220. doi: 10.1016/j.rbmo.2016.10.013\n- Shen X, Duan H, Wang S, et al. Expression of Cannabinoid Receptors in Myometrium and its Correlation With Dysmenorrhea in Adenomyosis. Reprod Sci. 2019;26(12):1618–1625. doi: 10.1177/1933719119833483 EDN: GLRLID\n- Zhang Y, Yu P, Sun FJ, et al. Expression of oxytocin receptors in the uterine junctional zone in women with adenomyosis. Acta Obstet Gynecol Scand. 2015;94(4):412–8. doi: 10.1111/aogs.12595\n- Vannuccini S, Luisi S, Tosti C, et al. Role of medical therapy in the management of uterine adenomyosis. Fertil Steril. 2018;109(3):398–405. doi: 10.1016/j.fertnstert.2018.01.013 EDN: YGYSUP\n- Strowitzki T, Marr J, Gerlinger C, et al. Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial. Hum Reprod. 2010;25(3):633–41. doi: 10.1093/humrep/dep469\n- Yarmolinskaya MI, Shalina MA, Beganova AK, Seyidova CI. Prospects for the combined use of trans-resveratrol and indole-3-carbinol in endometriosis. Obstetrics and Gynecology. 2022;(4):14–24. doi: 10.18565/aig.2022.4.14-24 EDN: IEOGPS","source_license":"CC0","license_restricted":false}